Active	Status	Sponsor type	Region	Phase	Filter
12 Active 10 Inactive 22 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Levy, Michael
PET-AON, NCT06453694: Efgartigimod for the Treatment of Acute Optic Neuritis	Not yet recruiting	2	20	US	Efgartigimod Alfa, Vyvgart Hytrulo, Placebo	Anastasia Vishnevetsky, MD, MPH, argenx	Optic Neuritis	12/26	07/27
SENS-NMO, NCT05974293: A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders	Not yet recruiting	2	44	US	Nabiximols, Sativex, Placebo	Michael, Levy M.D.,Ph.D., Jazz Pharmaceuticals	NMO Spectrum Disorder, Spasticity, Muscle	04/26	09/26
NCT05549258 / 2021-003528-33: Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder	Recruiting	2	15	Europe, Canada, US, RoW	Inebilizumab	Amgen, Horizon Therapeutics Ireland DAC	Neuromyelitis Optica Spectrum Disorder	04/27	04/27